E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018210 |
E.1.2 | Term | Gestational diabetes mellitus |
E.1.2 | System Organ Class | 100000004868 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
-To identify the best available measures to prevent GDM in an ongoing pregnancy
- Comparison of the impact of increased physical activity, enhanced nutrition and Vitamin D supplementation either alone or in combination on maternal glucose tolerance, maternal weight gain and insulin sensitivity |
|
E.2.2 | Secondary objectives of the trial |
To provide a cost-benefit calculation of GDM prevention for health care systems
o Completion of an economic evaluation of DALI preventive strategies
o Development of a decision tree to estimate cost-effectiveness of
prevention strategies
• To establish a pan-European cohort of mother-offspring pairs for future analyses with a central biobank and data base
o Creation of a comprehensive internet-based data base
o Creation of a physical store of placental tissue, maternal and cord blood (serum, DNA) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• pre-pregnancy BMI (self-reported weight, measured height) is ≥ 29 kg/m2)
• aged 18 years or more
• singleton pregnancy
• gestational age at recruitment < 17 weeks
• sufficiently fluent in major language of the country of recruitment
• being able to be moderately physically active
• giving written informed consent |
|
E.4 | Principal exclusion criteria |
• preexisting diabetes
• Diagnosed with (gestational) diabetes mellitus before randomisation defined as fasting glucose ≥ 5.1 mmol/l and/or 1 hour glucose ≥ 10 mmol/l and/or 2 hour glucose ≥8.5 mmol/l at baseline measurement.
• not able to walk at least 100 meters safely
• requirement for complex diets
• advanced chronic conditions (e.g. valvular heart disease)
• significant psychiatric disease
• unable to speak major language of the country of recruitment fluently |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Maternal:
• weight gain
• fasting glucose levels
• insulin sensitivity |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
24-28 and 35-37 weeks gestational age |
|
E.5.2 | Secondary end point(s) |
Maternal:
• Incidence of gestational diabetes
• Complications during pregnancy or delivery, such as preeclampsia, caesarean section rate, and need for labour induction
Foetal:
• Placental weight
• Birth weight and length
• Head and abdominal circumference
• Neonatal body composition
After birth:
• clinical outcomes such as jaundice, hypocalcaemia, neonatal intensive care unit (NICU) admission, respiratory distress |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
24-28 and 35-37 weeks gestational age and at birth |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
counseling on physical activity and/or healthy eating |
|
E.8.2.4 | Number of treatment arms in the trial | 8 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last recruited woman giving birth. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 13 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 13 |